Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.34 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.34 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.34 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1869619 | 0.86 | MAP2K1 (0.43) | MAP2K1MAP2K2 | |
| SCHEMBL1868069 | 0.86 | MAP2K1 (0.41) | MAP2K1MAP2K2 | |
| SCHEMBL1869645 | 0.86 | MAP2K1 (0.37) | MAP2K1 | |
| SCHEMBL1868120 | 0.86 | MAP2K1 (0.41) | MAP2K1MAP2K2 | |
| SCHEMBL1868918 | 0.85 | MAP2K1 (0.41) | MAP2K1MAP2K2MAP2K5CHEK1MAPK10 | |
| SCHEMBL1869320 | 0.84 | MAP2K1 (0.42) | MAP2K1MAP2K2MAP2K5EIF2AK1CHEK1 | |
| SCHEMBL1869049 | 0.83 | MAP2K1 (0.46) | MAP2K1MAP2K2MAP2K5EIF2AK1CHEK1 | |
| SCHEMBL1868346 | 0.82 | MAP2K1 (0.45) | MAP2K1MAP2K2MAP2K5EIF2AK1CHEK1 | |
| SCHEMBL1872689 | 0.81 | MAP2K1 (0.43) | MAP2K1MAP2K2MAP2K5CHEK1MAPK10 | |
| SCHEMBL1865131 | 0.80 | MAP2K1 (0.43) | MAP2K1MAP2K2MAP2K5EIF2AK1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190334-A1 | Heterocyclic Sulfonamide Derivatives | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | claimed |
| WO-2011054828-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES USEFUL AS MEK INHIBITORS | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | claimed |
| US-8466289-B2 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| US-8466289-B2 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2013-06-18 | — | — | US | disclosed |
| US-20110190334-A1 | Heterocyclic Sulfonamide Derivatives | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190334-A1 | Heterocyclic Sulfonamide Derivatives | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190334-A1 | Heterocyclic Sulfonamide Derivatives | NOVARTIS AG (CH) | 2011-08-04 | — | — | US | disclosed |
| WO-2011054828-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES USEFUL AS MEK INHIBITORS | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190334-A1 | Heterocyclic Sulfonamide Derivatives | BRAF, KSR2, NRAS | MAP2K1 269/4885MAP2K2 184/4885MAP2K5 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.